Newswise — Jeffrey H. Boatright, PhD, FARVO (Emory University School of Medicine) is the new president of the Association of Research in Vision and Ophthalmology (ARVO). He succeeds J. Mark Petrash, PhD, FARVO (University of Colorado), whose one-year term ended in May.
Robert Francis Miller, MD (University of Minnesota) and Paul Mitchell, MD, PhD, FARVO (University of Sydney) will serve as vice presidents. Peng T. Khaw, MD, PhD, FARVO (Moorfields Eye Hospital and UCL Institute of Ophthalmology) has been named president-elect and will serve the 2012 – 2013 term. Jacob Pe’er, MD, FARVO (Hadassah-Hebrew University Medical Center) is the vice-president-elect for that term.
In addition, ARVO members elected three new trustees to the board. Dimitri Azar, MD, FARVO, will represent the Cornea (CO) Section; Linda McLoon, PhD, FARVO, is the new Eye movements/ Strabismus/Amblyopia/Neuro-Ophthalmology (EY) trustee; and John Clarke, PhD, FARVO, is representing the Lens (LE) Section.
The new trustees’ terms began immediately after the 2011 Annual Meeting this month. ARVO trustees serve a five-year term.
"I am looking forward to the coming year," Boatright said. "It's an honor to serve as president of such a diverse organization, comprised of remarkably talented scientists and members across the globe who work collaboratively to make a difference in the field of vision and ophthalmology."
Biographical Sketches
President: Jeffrey. H. Boatright, PhD, FARVO
Boatright is a graduate of Brown University (ScB in neural sciences and experimental psychology) and Emory University (PhD in Pharmacology and the Neurosciences Training Program) and currently is an associate professor of ophthalmology at Emory University. He joined the faculty of the Department of Ophthalmology in 1999, conducting research on the regulation of retinal gene expression. This research expanded into using endogenous DNA repair mechanisms to treat genetic mutations that lead to blindness. Additional recent interests include development and preclinical assessment of neuroprotectants in treatment of retinal degenerations and development of new approaches to drug delivery to the posterior eye. Boatright is founding and current editor-in-chief of Molecular Vision. He has been an ARVO member since 1989, and in 2010 Boatright was named a Fellow of ARVO (FARVO). Currently, he is principal investigator or co-investigator in three NEI grants and two private foundation grants.
Vice President: Robert Francis Miller, MD
Miller is a professor in the Department of Neuroscience at the University of Minnesota. He attended medical school at the University of Utah and completed his postdoc at Wilmer Institute, Johns Hopkins University. The main focus of Miller’s research lies in mechanisms of synaptic transmission in the retina, computational neuroscience, glial cell physiology and neurocircuitry. He has over 10 works that are published and has received the Mortar Board Award for excellence in undergraduate teaching in 2000, and the Boycott Award for research in 2002. Miller has been a member of ARVO since 1969 and was awarded the association’s Proctor Medal in 2008 for his seminal discoveries on the basic mechanisms through which nerve cells of the retina communicate.
Vice President: Paul Mitchell, MD, PhD, FARVO
Mitchell is a medical retinal specialist and professor of ophthalmology at the University of Sydney, and director of Ophthalmology for the Sydney West Area. His clinical work focuses on the management of AMD, diabetic and other vascular retinopathies and on systemic diseases and their effects on the eye. Mitchell joined ARVO in 1990 and has served as chair of the Clinical/Epidemiologic Research Section Program Committee and as a member of the ARVO Awards Committee; he was nominated for trustee in 2003. He has made significant contributions in the fields of public health and ophthalmic epidemiology via the landmark Blue Mountains Eye Study (BMES) that has already yielded articles in close to 300 international publications including in the New England Journal of Medicine (NEJM). Currently Mitchell is director of the Center for Vision Research. He received the 2004 Association of International Glaucoma Societies award for research into the epidemiology of glaucoma.
President-elect: Peng T. Khaw, MD, PhD, FRCOpth, FRCP, FRCPath, FIBiol, FMedSci, FARVO
Khaw is a professor of glaucoma and ocular healing and a consultant ophthalmic surgeon at the Moorfields Eye Hospital and UCL Institute of Ophthalmology. Current research interests include wound healing, glaucoma surgery, stem cells and optic nerve regeneration. Khaw has been an ARVO member since 1990 and has served as a member and chair of the Glaucoma Section Program Committee, and received the first ARVO Pfizer Translational Award in 2005. He also holds membership in the British Academy of Medical Science; Royal College of Ophthalmologists, U.K.; American Academy of Ophthalmology; Glaucoma Research Society; European Glaucoma Society and International Glaucoma Association.
Vice President-elect: Jacob Pe’er, MD, FARVO
Pe’er graduated from the Hadassah-Hebrew University School of Medicine and completed residency in ophthalmology at Hadassah University Hospital. He currently is head of ophthalmology at Hadassah University Hospital, where he also served as chairman of the department of ophthalmology and head of the ocular oncology service. Pe’er’s fields of clinical expertise are general ophthalmology, ocular oncology, ocular pathology and pediatric ophthalmology. He joined ARVO in 1983 and has chaired the Anatomy Pathology Section Program Committee and International Members Committee and was a member of the Long-Range Planning Committee. Pe’er’s research focuses on ocular tumors; normal and pathologic cell proliferation; and vasculogenesis, angiogenesis and neovascularization of ocular tissue and intraocular tumors.
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include more than 12,500 eye and vision researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology. For more information, visit www.arvo.org.
All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.
No comments:
Post a Comment